Depersonalization disorder: pharmacological approaches

References

• American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorder 4th Edition. American Psychiatric Press, Washington DC, USA (1994).
   Google Scholar
• The ICD-10 Classification of Mental and Behavioural Disorders: 10th Edition. World Health Organization, Geneva, Switzerland (1992).
   Google Scholar
• Sierra M, Baker D, Medford N et al. Unpacking the depersonalization syndrome: an exploratory factor analysis on the Cambridge Depersonalization Scale. Psychol. Med.35(10), 1523–1532 (2005).
   PubMed Web of Science ®Google Scholar
• Hunter ECM, Sierra M, David AS. The epidemiology of depersonalization and derealization: a systematic review. Soc. Psychiatry Psychiatr. Epidemiol.39(1), 9–18 (2004).
   PubMed Web of Science ®Google Scholar
• Mula M, Pini S, Cassano GB. The neurobiology and clinical significance of depersonalization in mood and anxiety disorders: a critical reappraisal. J. Affect Disord.99(1–3), 91–99 (2007).
   PubMed Web of Science ®Google Scholar
• Marquez M, Segui J, Garcia L et al. Is panic disorder with psychosensorial symptoms (depersonalization-derealization) a more severe clinical subtype? J. Nerv. Ment. Dis.189(5), 332–335 (2001).
   PubMed Web of Science ®Google Scholar
• Maggini C, Raballo A, Salvatore P. Depersonalization and basic symptoms in schizophrenia. Psychopathology35(1), 17–24 (2002).
   PubMedGoogle Scholar
• Nuller YL. Depersonalisation – symptoms, meaning, therapy. Acta Psychiatr. Scand.66(6), 451–458 (1982).
   PubMed Web of Science ®Google Scholar
• Baker D, Hunter E, Lawrence E et al. Depersonalisation disorder: clinical features of 204 cases. Br. J. Psychiatry182(5), 428–433 (2003).
   PubMed Web of Science ®Google Scholar
• Simeon D, Knutelska M, Nelson D et al. Feeling unreal: a depersonalization disorder update of 117 cases. J. Clin. Psychiatry64(9), 990–997 (2003).
   PubMed Web of Science ®Google Scholar
• Johnson JG, Cohen P, Kasen S et al. Dissociative disorders among adults in the community, impaired functioning, and axis I and II comorbidity. J. Psychiatr. Res.40(2), 131–140 (2006).
   PubMed Web of Science ®Google Scholar
• Sierra M, Berrios GE Depersonalization: neurobiological perspectives. Biol. Psychiatry44(9), 898–908 (1998).
   Google Scholar
• Phillips ML, Medford N, Senior C et al. Depersonalization disorder: thinking without feeling. Psychiatry Res. Neuroimag.108(3), 145–160 (2001).
   PubMed Web of Science ®Google Scholar
• Lemche E, Surguladze SA, Giampietro VP et al. Limbic and prefrontal responses to facial emotion expressions in depersonalization. Neuroreport18(5), 473–477 (2007).
   PubMed Web of Science ®Google Scholar
• Medford N, Brierley B, Brammer M et al. Emotional memory in depersonalization disorder: a functional MRI study. Psychiatry Res.148(2–3), 93–102 (2006).
   PubMedGoogle Scholar
• Sierra M, Senior C, Dalton J et al. Autonomic response in depersonalization disorder. Arch. Gen. Psychiatry59(9), 833–838 (2002).
   PubMed Web of Science ®Google Scholar
• Sierra M, Senior C, Phillips ML et al. Autonomic response in the perception of disgust and happiness in depersonalization disorder. Psychiatry Res.145(2–3), 225–231 (2006).
   PubMed Web of Science ®Google Scholar
• Simeon D, Guralnik O, Knutelska M et al. Basal norepinephrine in depersonalization disorder. Psychiatry Res.121(1), 93–97 (2003).
   PubMed Web of Science ®Google Scholar
• Simeon D, Hollander E, Stein DJ et al. Induction of depersonalization by the serotonin agonist meta-chlorophenylpiperazine. Psychiatry Res.58(2), 161–164 (1995).
   PubMed Web of Science ®Google Scholar
• Wittmann M, Carter O, Hasler F et al. Effects of psilocybin on time perception and temporal control of behaviour in humans. J. Psychopharmacol.21(1), 50–64 (2007).
   PubMedGoogle Scholar
• Melges FT, Tinklenberg JR, Hollister LE et al. Temporal disintegration and depersonalization during marihuana intoxication. Arch. Gen. Psychiatry23(3), 204–210 (1970).
   PubMedGoogle Scholar
• Nakazi U, Bauer T, Nickel M et al. Inhibition of serotonin release in the mouse brain via presynaptic cannabinoid CB1 receptors. Naunyn-Schmiedeberg’s Arch. Pharmacol.361(1), 19–24 (2000).
   Google Scholar
• Russo EB, Burnett A, Hall B et al. Agonistic properties of cannabidiol at 5-HT1A receptors. Neurochem. Res.30(8), 1037–1043 (2005).
   PubMed Web of Science ®Google Scholar
• Hill MN, Sun JC, Tse MT et al. Altered responsiveness of serotonin receptor subtypes following long-term cannabinoid treatment. Int. J. Neuropsychopharmacol.9(3), 277–286 (2006).
   PubMed Web of Science ®Google Scholar
• Mathew RJ, Wilson WH, Humphreys D et al. Depersonalization after marijuana smoking. Biol. Psychiatry33(6), 431–441 (1993).
   PubMed Web of Science ®Google Scholar
• Hollander E, Liebowitz MR, DeCaria C et al. Treatment of depersonalization with serotonin reuptake blockers. J. Clin. Psychopharmacol.10(3), 200–203 (1990).
   PubMedGoogle Scholar
• Simeon D, Guralnik O, Schmeidler J et al. Fluoxetine therapy in depersonalisation disorder: randomised controlled trial. Br. J. Psychiatry.185(7), 31–36 (2004).
   PubMed Web of Science ®Google Scholar
• Simeon D, Stein DJ, Hollander E. Treatment of depersonalization disorder with clomipramine. Biol. Psychiatry44(4), 302–303 (1998).
   PubMedGoogle Scholar
• Lambert MV, Senior C, Phillips ML et al. Depersonalization in cyberspace. J. Nerv. Ment. Dis.188(11), 764–771 (2000).
   PubMedGoogle Scholar
• Sachdev P. Citalopram–clonazepam combination for primary depersonalization disorder: a case report. Aust. NZ J. Psychiatry36(3), 424–425 (2002).
   PubMedGoogle Scholar
• Stein MB, Uhde TW. Depersonalization disorder: effects of caffeine and response to pharmacotherapy. Biol. Psychiatry26(3), 315–320 (1989).
   PubMedGoogle Scholar
• Chambers RA, Bremner JD, Moghaddam B et al. Glutamate and post-traumatic stress disorder: toward a psychobiology of dissociation. Semin. Clin. Neuropsychiatry4(4), 274–281 (1999).
   PubMedGoogle Scholar
• Krystal JH, Karper LP, Seibyl JP et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch. Gen. Psychiatry51(3), 199–214 (1994).
   PubMed Web of Science ®Google Scholar
• Abel KM, Allin MP, Kucharska-Pietura K et al. Ketamine alters neural processing of facial emotion recognition in healthy men: an fMRI study. Neuroreport14(3), 387–391 (2003).
   PubMedGoogle Scholar
• Anand A, Charney DS, Oren DA et al. Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-d-aspartate receptor antagonists. Arch. Gen. Psychiatry57(3), 270–276 (2000).
   PubMed Web of Science ®Google Scholar
• Sierra M, Phillips ML, Ivin G et al. A placebo-controlled, cross-over trial of lamotrigine in depersonalization disorder. J. Psychopharmacol.17(1), 103–105 (2003).
   PubMedGoogle Scholar
• Sierra M, Phillips ML, Lambert MV et al. Lamotrigine in the treatment of depersonalization disorder. J. Clin. Psychiatry62(10), 826–827 (2001).
   PubMedGoogle Scholar
• Sierra M, Baker D, Medford N et al. Lamotrigine as an add-on treatment for depersonalization disorder: a retrospective study of 32 cases. Clin. Neuropharmacol.29(5), 253–839 (2006).
   PubMedGoogle Scholar
• Cohen MR, Pickar D, Dubois M. The role of the endogenous opioid system in the human stress response. Psychiatr. Clin. North Am.6(3), 457–457 (1983).
   PubMed Web of Science ®Google Scholar
• Younger JW, Lawler-Row KA, Moe KA et al. Effects of naltrexone on repressive coping and disclosure of emotional material: a test of the opioid-peptide hypothesis of repression and hypertension. Psychosom. Med.68(5), 734–741 (2006).
   PubMed Web of Science ®Google Scholar
• Bandura A, Cioffi D, Taylor CB et al. Perceived self-efficacy in coping with cognitive stressors and opioid activation. J. Pers. Soc. Psychol.55(3), 479–488 (1988).
   PubMed Web of Science ®Google Scholar
• Cohen MR, Pickar D, Liberzon I et al. µ-opioid receptors and limbic responses to aversive emotional stimuli. Proc. Natl Acad. Sci. USA99(10), 7084–7089 (2002).
   PubMedGoogle Scholar
• Kennedy SE, Koeppe RA, Young EA et al. Dysregulation of endogenous opioid emotion regulation circuitry in major depression in women. Arch Gen. Psychiatry63(11), 1199–1208 (2006).
   PubMed Web of Science ®Google Scholar
• Eriksson E, Westberg P, Thuresson K et al. Increased cerebrospinal fluid of endorphin immunogeactivity in panic disorder. Neuropsychopharmacology2(3), 225–228 (1989).
   PubMedGoogle Scholar
• Dager SR, Cowley DS, Dorsa DM et al. Plasma β-endorphin response to lactate infusion. Biol. Psychiatry25(2), 243–245 (1989).
   PubMedGoogle Scholar
• Ball S, Robinson A, Shekhar A et al. Dissociative symptoms in panic disorder. J. Nerv. Ment. Dis.185(12), 755–760 (1997).
   PubMed Web of Science ®Google Scholar
• Bryant RA, Panasetis P The role of panic in acute dissociative reactions following trauma. Br. J. Clin. Psychol.44(Pt 4), 489–494 (2005).
   PubMedGoogle Scholar
• Nixon RD, Bryant RA. Peritraumatic and persistent panic attacks in acute stress disorder. Behav. Res. Ther.41(10), 1237–1242 (2003).
   PubMed Web of Science ®Google Scholar
• Pfeiffer A, Brantl V, Herz A et al. Psychotomimesis mediated by κ opiate receptors. Science233(4765), 774–776 (1986).
   PubMed Web of Science ®Google Scholar
• Walsh SL, Strain EC, Abreu ME et al. Enadoline, a selective κ opioid agonist: comparison with butorphanol and hydromorphone in humans. Psychopharmacology (Berl).157(2), 151–162 (2001).
   PubMed Web of Science ®Google Scholar
• Brunton L, Lazo J, Parker K. Goodman & Gilman’s The Pharmacological basis of therapeutics (10th Edition). McGraw Hill, NY, USA (2001).
   Google Scholar
• Glover H. A preliminary trial of nalmefene for the treatment of emotional numbing in combat veterans with post-traumatic stress disorder. Isr. J. Psychiatry Relat. Sci.30(4), 255–263 (1993).
   PubMed Web of Science ®Google Scholar
• Lubin G, Weizman A, Shmushkevitz M et al. Short-term treatment of post-traumatic stress disorder with naltrexone: an open-label preliminary study. Hum. Psychopharmacol.17(4), 181–185 (2002).
   PubMed Web of Science ®Google Scholar
• Bohus MJ, Landwehrmeyer GB, Stiglmayr CE et al. Naltrexone in the treatment of dissociative symptoms in patients with borderline personality disorder: an open-label trial. J. Clin. Psychiatry60(9), 598–603 (1999).
   PubMed Web of Science ®Google Scholar
• Philipsen A, Schmahl C, Lieb K. Naloxone in the treatment of acute dissociative states in female patients with borderline personality disorder. Pharmacopsychiatry37(5), 196–199 (2004).
   PubMed Web of Science ®Google Scholar
• Moroz BT, Nuller IL, Ustimova IN et al. Study of pain sensitivity based on the indicators of electro-odontometry in patients with depersonalization and depressive disorders. Z. Nevropatol. Psikhiatr. Im. S. S. Korsakova90(10), 81–82 (1990).
   PubMedGoogle Scholar
• Abugova MA. Indices of pain threshold as a method of objective assessment of depersonalization therapy efficacy. Bekhterev. Rev. Psychiatry Med. Psychol.4, 120–122 (1996).
   Google Scholar
• Roder CH, Michal M, Overbeck G et al. Pain response in depersonalization: a functional imaging study using hypnosis in healthy subjects. Psychother. Psychosom.76(2), 115–121 (2007).
   PubMed Web of Science ®Google Scholar
• Frew AK, Drummond PD. Negative affect, pain and sex: the role of endogenous opioids. Pain132(Suppl. 1), S77–S85 (2007).
   Google Scholar
• Nuller YL, Morozova MG, Kushnir ON et al. Effect of naloxone therapy on depersonalization: a pilot study. J. Psychopharmacol.15(2), 93–95 (2001).
   PubMed Web of Science ®Google Scholar
• Simeon D, Knutelska M. An open trial of naltrexone in the treatment of depersonalization disorder. J. Clin. Psychopharmacol.25(3), 267–270 (2005).
   PubMedGoogle Scholar
• Hood SD, Hince DA, Robinson H. Serotonin regulation of the human stress response. Psychoneuroendocrinology31(9), 1087–1097 (2006).
   PubMedGoogle Scholar
• Akirav I, Maroun M. The role of the medial prefrontal cortex–amygdala circuit in stress effects on the extinction of fear. Neural Plast. (2007) (Epub ahead of print).
   PubMedGoogle Scholar
• Ballon JS, Feifel D. A systematic review of modafinil: potential clinical uses and mechanisms of action.J. Clin. Psychiatry67(4), 554–566 (2006).
   PubMed Web of Science ®Google Scholar
• Griebel G, Stemmelin J, Scatton B. Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents. Biol. Psychiatry57(3), 261–267 (2005).
   PubMed Web of Science ®Google Scholar
• Metcalf MD, Coop A. κ opioid antagonists: past successes and future prospects. AAPS J.7(3), 704–722 (2005).
   Google Scholar